Akero Therapeutics is a clinical-stage company developing treatments for serious metabolic diseases, including NASH. Their lead product candidate, EFX, regulates metabolism and is being evaluated in a Phase 2b clinical trial for NASH patients. Formerly known as Pippin Pharmaceuticals, the company was incorporated in 2017 and is based in South San Francisco.